BRAF, KRAS, and EGFR mutations in recurrent thyroid cancer may benefit from targeted therapies and further study on these mutations with their risk of recurrence, distant metastasis, and overall prognosis in thyroid cancers may be required. This evidence concerns the gene KRAS and thyroid cancer.